期刊文献+

CYP2D6^*10基因多态性对喹硫平血药浓度和临床疗效的影响 被引量:4

Effect of CYP2D6^*10 Genetic Polymorphism on Blood Concentration and Clinical Efficacy of Quetiapine
原文传递
导出
摘要 目的探讨细胞色素P4502D6(CYP2D6)基因多态性对精神分裂症患者喹硫平血药浓度和临床疗效的影响,为喹硫平的个体化给药提供参考。方法选取符合诊断标准的精神分裂症住院患者98例,接受喹硫平单一治疗,剂量范围为100~750 mg·d^-1,观察疗程为4周。采用多重高温连接酶检测反应技术检测CYP2D6*10基因多态性,采用UPLC-MS/MS测定喹硫平血药浓度,以治疗前后阳性和阴性症状量表(PANSS)评分变化评价临床疗效,并比较不同基因型之间喹硫平血药浓度和临床疗效的差异。结果TT型患者喹硫平血药浓度明显高于CC型和CT型患者(P<0.05),且喹硫平血药浓度与CYP2D6^*10基因型存在相关关系(r=0.558,P<0.001);TT型患者治疗有效率最高,CT型次之,CC型最低,差异有统计学意义(P<0.05);治疗后TT型患者PANSS量表总减分值、阳性症状减分值和阴性症状减分值均明显高于CC型患者(P<0.05)。结论CYP2D6*10基因多态性可影响喹硫平血药浓度和临床疗效,CC型患者用喹硫平治疗时血药浓度偏低且疗效较差,临床医生用药时应予以关注。 OBJECTIVE To investigate the effect of cytochrome P4502 D6(CYP2 D6)genetic polymorphism on blood concentration and clinical efficacy of quetiapine in schizophrenia patients,and to provide evidence for the individualized administration of quetiapine.METHODS A total of 98 patients with schizophrenia were selected and treated with quetiapine alone at a dose ranging from 100 to 750 mg·d^-1 for 4 weeks.The genetic polymorphism of CYP2 D6^*10 was detected by improved multiple ligase detection reaction.The blood concentration of quetiapine was determined by UPLC-MS/MS.Positive and negative syndrome scale(PANSS)questionnaire were used to estimate the response to quetiapine treatment.Then the differences in blood concentration and clinical efficacy of quetiapine among different genotypes were compared.RESULTS The blood concentration of quetiapine in type of TT was significantly higher than that in types of CC and CT(P<0.05).The blood concentration of quetiapine was correlated with CYP2 D6*10 genotype(r=0.558,P<0.001).TT type patients had the highest treatment efficiency,followed by CT type and CC type,and the difference was statistically significant(P<0.05).The reductions of PANSS total score,positive symptom score and negative symptom score in TT type patients were significantly higher than that in type of CC after treatment(P<0.05).CONCLUSION CYP2 D6*10 genetic polymorphism can affect the blood concentration and clinical efficacy of quetiapine.Patients with CC type have low blood concentration of quetiapine and poor clinical efficacy,so clinicians shall pay appropriate attention to it.
作者 闫盼 宋明芬 方海红 李静 王晟东 施剑飞 YAN Pan;SONG Mingfen;FANG Haihong;LI Jing;WANG Shengdong;SHI Jianfei(Hangzhou Seventh People’s Hospital,Hangzhou 310013,China;Mental Health Centre of Zhejiang University School of Medicine,Hangzhou 310013,China;Anhui Medical University,Hefei 230032,China)
出处 《中国现代应用药学》 CAS CSCD 北大核心 2020年第14期1747-1750,共4页 Chinese Journal of Modern Applied Pharmacy
基金 浙江省科技计划项目(2015C03054) 浙江省医药卫生科技计划项目(2020KY2222,2020KY744) 杭州市医药卫生科技项目(OO20190509)。
关键词 精神分裂症 喹硫平 CYP2D6*10基因多态性 血药浓度 临床疗效 schizophrenia quetiapine CYP2D6*10 genetic polymorphism blood concentration clinical efficacy
  • 相关文献

参考文献3

二级参考文献48

  • 1傅崇铭,张桂华,唐茂芹,郭瑞臣.精神分裂症患者富马酸喹硫平血药浓度测定及其与临床效应的相关性[J].中国药学杂志,2004,39(12):928-930. 被引量:15
  • 2Lamba JK, Lin YS, Thummel K, et al. Common allelic variants ofcytochrome P4503A4 and their prevalence in different populations [J]. Pharmacogenetics, 2002,12(2) , 121-132.
  • 3Bakken GV, Molden E, Knutsen K, et al. Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro [J]. Drug Metab Dispos,2012, 40(9) : 1778-1784.
  • 4Wang D, Guo Y, Wrighton SA, et al. Intronic polymorphism in CYP3A4affects hepatic expression and response to statin drugs [ J ]. Pharmacogenomics, 2011,11 ( 4 ) : 274-286.
  • 5van der Weide K, van der Weide J. The influence of the CYP3A4- 22 polymorphism on serum concentration of quetiapine in psychiatric patients [ J]. J Chin Psychopharmacol, 2014,34(2) : 256-260.
  • 6Stockmann C, Fassl B, Gaedigk R, et al. Fluticasone propio- natepharmacogenetics: CYP3A4+ 22 polymorphism and pediatric asthmacontrol [ J ]. J Pediatr, 2013, 162 (6) : 1222-1227.
  • 7Langaee TY, Gong Y, Yarandi HN, et al. Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil [ J ]. Clin Pharmacol Ther, 2007, 81 (3) : 386-391.
  • 8Liu L, Yang L, Zhang YC, et al. Polymorphisms of drug- metabolizing enzymes genes in a Han Chinese population [ J ]. Zhonghua Yi Xue Za Zhi,2009, 89 (38) : 2675-2681.
  • 9Kim KA, Joo HJ, Lee HM, et al. Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers [ J ]. Pharmacogenet Genomics,2014,24( 1 ) : 35-42.
  • 10SAR Shilbayeh SS, Melhem M. Quantitation of the impact of CYP3A5 A6986G polymorphism on quetiapine pharmacokinetics by simulation of target attainment [ J ]. Clin Pharmacol Drug Dev, 2015 ,4(5) :387-394.

共引文献13

同被引文献29

引证文献4

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部